BOSTON and LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed ...

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins University, has developed a compound that could ...

The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...

Credit: IOCB Prague Alopecia areata is an autoimmune disorder in which the immune system attacks hair follicles, leading to their inflammation and consequently to hair loss and impaired hair growth.

ORLANDO, FLA. — Janus kinase (JAK) inhibitors have revolutionized the treatment of alopecia areata (AA), and more drugs in this class are still in development for AA. However, a new therapy with ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...